By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GlaxoSmithKline will use Cellzome's chemical proteomics platform to identify potential candidates for small-molecule drugs for immunoinflammatory disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.